Juxiang Xiao

1.2k total citations · 1 hit paper
14 papers, 440 citations indexed

About

Juxiang Xiao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Juxiang Xiao has authored 14 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Juxiang Xiao's work include Gastric Cancer Management and Outcomes (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Juxiang Xiao is often cited by papers focused on Gastric Cancer Management and Outcomes (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Juxiang Xiao collaborates with scholars based in China, United States and Malaysia. Juxiang Xiao's co-authors include Jieer Ying, Yuxian Bai, Shukui Qin, Zhendong Chen, Xiaohong Chen, Abby B. Siegel, Chunyi Hao, Ruocai Xu, Zhenggang Ren and Baek‐Yeol Ryoo and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and World Journal of Gastroenterology.

In The Last Decade

Juxiang Xiao

14 papers receiving 437 citations

Hit Papers

Pembrolizumab Versus Placebo as Second-Line Therapy in Pa... 2022 2026 2023 2024 2022 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
    2022 127 citations Shukui Qin, Zhendong Chen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Juxiang Xiao China 10 275 163 157 107 68 14 440
Quanren Wang China 1 245 0.9× 131 0.8× 148 0.9× 61 0.6× 29 0.4× 2 368
Philip He United States 7 279 1.0× 270 1.7× 106 0.7× 72 0.7× 82 1.2× 22 459
L.-T. Chen Taiwan 10 170 0.6× 254 1.6× 115 0.7× 132 1.2× 238 3.5× 19 511
Thomas Cheung Yau Hong Kong 9 249 0.9× 277 1.7× 76 0.5× 51 0.5× 91 1.3× 21 452
Toshiro Ogura Japan 11 270 1.0× 94 0.6× 162 1.0× 108 1.0× 107 1.6× 45 554
Álvaro Díaz‐González Spain 15 140 0.5× 253 1.6× 111 0.7× 173 1.6× 169 2.5× 41 567
Guoliang Shao China 9 155 0.6× 375 2.3× 138 0.9× 87 0.8× 134 2.0× 34 553
Quan Bao China 10 201 0.7× 284 1.7× 87 0.6× 161 1.5× 55 0.8× 36 469
Niek A. Peters Netherlands 11 246 0.9× 48 0.3× 80 0.5× 137 1.3× 51 0.8× 15 383
Han Qi China 11 151 0.5× 158 1.0× 201 1.3× 66 0.6× 58 0.9× 45 375

Countries citing papers authored by Juxiang Xiao

Since Specialization
Citations

This map shows the geographic impact of Juxiang Xiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juxiang Xiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juxiang Xiao more than expected).

Fields of papers citing papers by Juxiang Xiao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juxiang Xiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juxiang Xiao. The network helps show where Juxiang Xiao may publish in the future.

Co-authorship network of co-authors of Juxiang Xiao

This figure shows the co-authorship network connecting the top 25 collaborators of Juxiang Xiao. A scholar is included among the top collaborators of Juxiang Xiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juxiang Xiao. Juxiang Xiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Qin, Shukui, Zhendong Chen, Weijia Fang, et al.. (2022). Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 41(7). 1434–1443. 127 indexed citations breakdown →
2.
Qin, Shukui, Zhendong Chen, Weijia Fang, et al.. (2022). Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.. Journal of Clinical Oncology. 40(4_suppl). 383–383. 79 indexed citations
3.
Peng, Zhi, Jia Wei, Wang Feng, et al.. (2021). Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research. 27(11). 3069–3078. 75 indexed citations
4.
Li, Zhigang, Feng Ye, Dong Ma, et al.. (2021). First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.. Journal of Clinical Oncology. 39(15_suppl). 4049–4049. 16 indexed citations
5.
Huang, Jing, Juxiang Xiao, Wentao Fang, et al.. (2021). Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial. Cancer Medicine. 10(5). 1681–1689. 51 indexed citations
6.
Song, Yan, Juxiang Xiao, Wentao Fang, et al.. (2021). The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. Cancer Biology and Medicine. 18(2). 562–568. 8 indexed citations
7.
Xu, Jianming, Yi Li, Qingxia Fan, et al.. (2020). Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).. Journal of Clinical Oncology. 38(15_suppl). 4511–4511. 17 indexed citations
8.
Huang, Jing, Juxiang Xiao, Wentao Fang, et al.. (2019). Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial.. Journal of Clinical Oncology. 37(4_suppl). 95–95. 13 indexed citations
9.
10.
Wang, Hejing, Junmin Qian, Ya‐Ping Zhang, et al.. (2017). Growth of MCF-7 breast cancer cells and efficacy of anti-angiogenic agents in a hydroxyethyl chitosan/glycidyl methacrylate hydrogel. Cancer Cell International. 17(1). 55–55. 25 indexed citations
11.
Chen, Lihong, Meng Du, Lei Zhao, et al.. (2014). Selective colorectal cancer cell lysates enhance the immune function of mature dendritic cells in vitro. Molecular Medicine Reports. 11(3). 1877–1884. 4 indexed citations
12.
Tu, Honglei, et al.. (2011). [Role of oxidative stress and thioredoxin in gastric cancer].. PubMed. 31(9). 1518–20. 1 indexed citations
13.
Xiao, Juxiang. (2005). B7molecule mRNA expression in colorectal carcinoma. World Journal of Gastroenterology. 11(36). 5655–5655. 11 indexed citations
14.
Xiao, Juxiang, et al.. (2005). [Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications].. PubMed. 85(30). 2136–9. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Quanren Wang Breakdown of academic impact, for papers by Philip He Breakdown of academic impact, for papers by L.-T. Chen Breakdown of academic impact, for papers by Thomas Cheung Yau Breakdown of academic impact, for papers by Toshiro Ogura Breakdown of academic impact, for papers by Álvaro Díaz‐González Breakdown of academic impact, for papers by Guoliang Shao Breakdown of academic impact, for papers by Quan Bao Breakdown of academic impact, for papers by Niek A. Peters Breakdown of academic impact, for papers by Han Qi
Rankless by CCL
2026